Patient P-01349

Synthetic patientNBL-101 · Day 120 · 35–44 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Stable

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

72%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 43 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 69 GI symptom burden −26% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 43.

Primary contributors, last 14 days

Nutritional resilience+4
GI instability+3
Treatment adherence-3
Toxicity+3

What helped?

GI Support Protocol GI-04Day 60
Result: symptom burden −26%

LIFE OS recommendation

Dietary Support Protocol NP-02

59%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
- WearableHRV 29 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 38/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Autonomic recovery ↑45
- WearableResting HR 76 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.1 · butyrate capacity 38/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 6.5 h
Steps: 7,299
Resting HR: 75 bpm

Daily log: GI score 53, nutritional resilience 42, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01611	53%	S14	GI-04	improved	44
P-01705	53%	S14	GI-04	improved	39
P-01431	52%	S14	GI-04	improved	41
P-01433	52%	S14	GI-04	improved	48
P-01556	50%	S14	GI-04	improved	44
P-01496	49%	S14	SC-12	improved	46
P-01570	49%	S14	SC-12	improved	46
P-01786	49%	S07	ME-01	improved	46
P-01332	47%	S14	NP-02	improved	43
P-01402	47%	S04	GI-04	improved	37
P-01409	47%	S14	SC-12	improved	41
P-01429	47%	S09	GI-04	improved	45